[The thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio in pancreatic cancer]
Related Experiment Video
Updated: Aug 20, 2026
Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
Published on: February 2, 2024
Xian-jun Yu1, Yong-jian Jiang, De-liang Fu
1Pancreatic Cancer Center of Huashan Hospital, Shanghai 200040, China. yuxianjun@hotmail.com
Objective:
To determine the contents of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) in pancreatic cancer to provide a basis for the clinical use of capecitabine in pancreatic cancer patients.
Methods:
The contents of TP and DPD in pancreatic cancer and adjacent normal tissues from 20 patients were determined by ELISA and the TP to DPD ratios in the cancer and adjacent normal tissue were compared.
Results:
TP content was 5- to 283-fold higher in tumor tissue (mean 74-fold) than in the adjacent normal tissue (P < 0.01). DPD in the cancer tissue increased significantly. So did the TP to DPD ratio, when compared to that in normal pancreatic tissue (P < 0.01).
Conclusion:
The increased TP to DPD ratio in pancreatic cancer suggests that capecitabine could be activated by the cancer, these capable of selectively kill the tumor cells.
